Who is sponsoring NCT05460650?

NCT05460650 is sponsored by University of Manchester.

What drugs are being tested in NCT05460650?

Interventions in NCT05460650: App Promoting Healthy Behaviours.

What condition does NCT05460650 study?

NCT05460650 studies Breast Cancer, Overweight and Obesity, Diet, Healthy, Weight Gain, Alcohol Drinking, Smoking Behaviors, Healthy Nutrition, Healthy Lifestyle, Healthy Eating Index.

Is NCT05460650 still recruiting?

NCT05460650 is currently completed. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT05460650

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acceptance and Usability of an App Promoting Healthy Behaviours Amongst Young Women at Increased Risk of Breast Cancer

Completed NA Last updated 29 March 2023

What this trial tests

NA trial testing App Promoting Healthy Behaviours in Breast Cancer in 35 participants. Completed in 10 March 2023.

Timeline

3 November 2022

Primary endpoint
10 March 2023

10 March 2023

Quick facts

Lead sponsor	University of Manchester
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	35
Start date	3 November 2022
Primary completion	10 March 2023
Estimated completion	10 March 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

App Promoting Healthy Behaviours

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Overweight and Obesity — all drugs for Overweight and Obesity →
Diet, Healthy — all drugs for Diet, Healthy →
Weight Gain — all drugs for Weight Gain →

Sponsor

University of Manchester

Who can join

Adults 18 to 35, female only, with Breast Cancer or Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is estimated that around 20% of breast cancers (BC) in the UK are preventable through adherence to appropriate health behaviours, i.e., healthy diet, physical activity, limited alcohol, not smoking, and that women at increased risk of BC could benefit from greater decreases in risk than the general population via health behaviour changes. Young women (age \<35 years) who are at increased risk of developing BC currently receive little or no information regarding health behaviours and BC risk, or support for behaviour change. This feasibility study aims to explore whether a novel app is acceptable to women at increased risk and could potentially engage them with improved health behaviours which could reduce their future risk of BC.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Evaluating the Acceptance and Usability of an App Promoting Weight Gain Prevention and Healthy Behaviors Among Young Women With a Family History of Breast Cancer: Protocol for an Observational Study.
Pegington M, Davies A, Mueller J, Cholerton R, et al · · 2022 · cited 3× · PMID 36525287 · DOI 10.2196/41246
Experiences of a Digital Behavior Change Intervention to Prevent Weight Gain and Promote Risk-Reducing Health Behaviors for Women Aged 18 to 35 Years at Increased Risk of Breast Cancer: Qualitative Interview Study.
Hawkes RE, Pegington M, Davies A, Mueller J, et al · · 2024 · PMID 39586077 · DOI 10.2196/57964

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other University of Manchester trials

Trials by the same sponsor.

NCT07506096 — Using IF-THEN Plans to Support Healthcare Professionals in Raising Patient Safety Concerns · NA · not yet recruiting
NCT07084090 — Using IF-THEN Plans to Support Patients in Raising Safety Concerns About Their Care · NA · not yet recruiting
NCT07494760 — A Feasibility Randomised Control Trial to Evaluate Early Perinatal Bereavement Counselling for Parents Who Have Experien · NA · not yet recruiting
NCT07372885 — GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia · Phase 1, PHASE2 · not yet recruiting
NCT07381894 — Multicentre Hypertrophic Cardiomyopathy Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05460650 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manchester
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05460650.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing